1/17/2026

Janusmed sex and gender

Janusmed sex and gender – atezolizumab

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
C C
C C

Atezolizumab

Atezolizumab

Class : C

Show all info

Print

Contact us

  1. Li C, Lei S, Ding L, Xu Y, Wu X, Wang H et al. Global burden and trends of lung cancer incidence and mortality. Chin Med J (Engl). 2023;136(13):1583-1590.

  2. Lampimukhi M, Qassim T, Venu R, Pakhala N, Mylavarapu S, Perera T et al. A Review of Incidence and Related Risk Factors in the Development of Hepatocellular Carcinoma. Cureus. 2023;15(11):e49429.

  3. Pignot G, Barthélémy P, Borchiellini D. Sex Disparities in Bladder Cancer Diagnosis and Treatment. Cancers (Basel). 2024;16(23):.

  4. Tecentriq (atezolizumab). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2025-10-16, cited 2025-12-14]

  5. Marchand M, Zhang R, Chan P, Quarmby V, Ballinger M, Sternheim N et al. Time-dependent population PK models of single-agent atezolizumab in patients with cancer. Cancer Chemother Pharmacol. 2021;88(2):211-221.

  6. Liu W, Huo G, Chen P. Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis. Front Immunol. 2022;13:909027.

  7. Schneidewind L, Kiss B, Zengerling F, Borkowetz A, Graf S, Kranz J et al. Gender-specific outcomes in immune checkpoint inhibitor therapy for advanced or metastatic urothelial cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2023;149(11):9399-9408.

  8. Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N et al. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021;39(6):619-630.

  9. May P, Winter C, Hubrecht I, Ortner E, Strathmeyer S, Geyer R et al. Metabolic phenotype and gender may predict treatment outcomes of atezolizumab in extensive-stage small cell lung cancer. Transl Lung Cancer Res. 2025;14(9):3836-3846.

  10. Mikami T, Liaw B, Asada M, Niimura T, Zamami Y, Green-LaRoche D et al. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database. J Neurooncol. 2021;152(1):135-144.

  11. Shan W, Zhu J, Shen J. Gender and age disparities in cardiac immune-related adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FAERS database. BMJ Open. 2025;15(6):e090087.

  1. Li C, Lei S, Ding L, Xu Y, Wu X, Wang H et al. Global burden and trends of lung cancer incidence and mortality. Chin Med J (Engl). 2023;136(13):1583-1590.
  2. Lampimukhi M, Qassim T, Venu R, Pakhala N, Mylavarapu S, Perera T et al. A Review of Incidence and Related Risk Factors in the Development of Hepatocellular Carcinoma. Cureus. 2023;15(11):e49429.
  3. Pignot G, Barthélémy P, Borchiellini D. Sex Disparities in Bladder Cancer Diagnosis and Treatment. Cancers (Basel). 2024;16(23):.
  4. Tecentriq (atezolizumab). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2025-10-16, cited 2025-12-14]
  5. Marchand M, Zhang R, Chan P, Quarmby V, Ballinger M, Sternheim N et al. Time-dependent population PK models of single-agent atezolizumab in patients with cancer. Cancer Chemother Pharmacol. 2021;88(2):211-221.
  6. Liu W, Huo G, Chen P. Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis. Front Immunol. 2022;13:909027.
  7. Schneidewind L, Kiss B, Zengerling F, Borkowetz A, Graf S, Kranz J et al. Gender-specific outcomes in immune checkpoint inhibitor therapy for advanced or metastatic urothelial cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2023;149(11):9399-9408.
  8. Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N et al. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021;39(6):619-630.
  9. May P, Winter C, Hubrecht I, Ortner E, Strathmeyer S, Geyer R et al. Metabolic phenotype and gender may predict treatment outcomes of atezolizumab in extensive-stage small cell lung cancer. Transl Lung Cancer Res. 2025;14(9):3836-3846.
  10. Mikami T, Liaw B, Asada M, Niimura T, Zamami Y, Green-LaRoche D et al. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database. J Neurooncol. 2021;152(1):135-144.
  11. Shan W, Zhu J, Shen J. Gender and age disparities in cardiac immune-related adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FAERS database. BMJ Open. 2025;15(6):e090087.